Li Kang Biomedical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 06, 2022 at 10:47 pm
Share
Li Kang Biomedical Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 101.33 million compared to TWD 93.62 million a year ago. Revenue was TWD 101.33 million compared to TWD 93.62 million a year ago. Net income was TWD 13.94 million compared to TWD 10.03 million a year ago. Basic earnings per share from continuing operations was TWD 0.6 compared to TWD 0.4286 a year ago. Diluted earnings per share from continuing operations was TWD 0.6 compared to TWD 0.4286 a year ago.
Li Kang Biomedical Co., Ltd. formerly BAFO TECHNOLOGIES CORP., is engaged in the manufacture and sale of computer, communication and consumer (3C) product cables and circumscribed computer peripheral products, as well as communication products. The Company offers unshielded twisted pair (UTP) cables, monitor cables, small computer system interface (SCSI) cables, universal serial bus (USB) cables, wireless hopping/mesh access points, wireless modules, and wireless vehicle communication systems, among others. The Company distributes its products within the domestic market and to overseas markets, including Europe, the Americas and the rest of Asia.
LI KANG BIOMEDICAL CO., LTD. 
